UNSPSC 51431613: Terodiline hydrochloride

This classification denotes a calcium channel blocker and parasympatholytic C20H27N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K2ZA89W43F, chemically known as benzenepropanamine, n-(1,1-dimethylethyl)-.alpha.-methyl-.gamma.-phenyl-, hydrochloride, but more generally known as terodiline hydrochloride, which bears US NIH Compound Identifier 23479. European Medicines Agency schedules Terodiline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04728MIG.

Most nations, for tariff and trade purposes, schedule terodiline hydrochloride under HS 29214980 and SITC 51454. As of Q4 2014, TERODILINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(CC(C1CCCCC1)C2CCCCC2)NC(C)(C)C.CL.

UNSPSC 51431613 Terodiline hydrochloride, a Commodity code, covers pharmaceutical active ingredients and finished medications used in emergency medical services and health benefit programs. Recent state and local solicitations under this code show procurement of advanced life support medications, generic multi-source pharmaceuticals, and over-the-counter products distributed through authorized wholesaler networks and emergency responder systems. Issuing bodies include municipal fire-rescue departments, state health and human services agencies, and multi-state cooperative purchasing alliances. Vendors supplying under this code must meet FDA compliance, Good Manufacturing Practices (cGMP) certification, and Drug Supply Chain Security Act (DSCSA) requirements, maintain expiration-date minimums (typically nine months to one year from delivery), and provide comprehensive safety documentation including Safety Data Sheets compliant with OSHA standards and accessibility conformance reports.

The City of Tampa Fire Rescue issued IFB 26P00188 in April 2026 for advanced life support medications including labetalol, epinephrine, adenosine, and diltiazem vials with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00, designating the opportunity as a sheltered Small Local Business Enterprise market with a 5 percent bid discount not to exceed $10,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to participating state and local government facilities in Minnesota and Oregon, with a proposal deadline of March 26, 2026 and price competitiveness weighted at 75 percent of evaluation criteria. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capabilities for establishing direct contracts outside traditional pharmacy benefit manager and wholesaler arrangements. Recent activity spans Florida, Texas, Minnesota, and Oregon, with cooperative purchasing vehicles and wholesaler-distributed supply chains dominating the procurement structure.